Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell Lung Carcinoma

Overview

The investigators propose to study the carbonic anhydrase inhibition (acetazolamide) associated with concomitant radiochemotherapy or radioimmunotherapy in small cell lung cancer due to: 1. The over-expression of carbonic anhydrases in this type of cancer, 2. The Anti-tumor effect in preclinical acetazolamide in various tumor lines including neuroendocrine tumor lines, 3. The observed synergy between irradiation and inhibition of carbonic anhydrases, 4. Potential anti-tumor immune effect caused by decreased extracellular acidity.

Detailed description

Compared with healthy cells, glucose metabolism is greatly modified in cancer cells because of their highly proliferative character. This differential tumor / healthy tissue property is an opportunity to be able to propose a treatment whose therapeutic gain can be major (targeted treatment). Preclinical studies are multiple and showed that the targeting of overexpressed proteins (carbonic anhydrases) and involved in glycolytic metabolism can lead to a significant anti-tumor effect. This has never been tested in humans.

Acetazolamide is a molecule commonly used for non carcinologic purposes but has demonstrated anti-tumor activity in preclinical studies; there is also synergy radiotherapy / targeting of carbonic anhydrases. Therefore, the investigators propose to study the combination of acetazolamide / radiotherapy / chemotherapy with platinum and etoposide in localized Small Cell Lung cancer, or associated with radioimmunotherapy (extensive SCLC).

This would be the first study:

* targeting glucose metabolism, * testing the effectiveness of acetazolamide in oncology, * testing the synergy radiotherapy / targeting glycolytic metabolism, * trying to manipulate the anti-tumor immune system indirectly, by decreasing extracellular acidosis.

Interventions

• Drug acetazolamide in combination with platinum and etoposide-based radiochemotherapy
  Radiation therapy will be combined with platinum and etoposide-based chemotherapy combined with 3-6 tablets per day of acetazolamide during the entire course of therapy (dosage appropriate to the inclusion phase).
• Drug acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC
  acetazolamide in combination with radioimmunotherapy in patients with extensive SCLC

Primary outcome measures

• To identify the Tolerated Maximum Dose (DMT) and Recommended Dose (DR) of acetazolamide in combination with radiotherapy combined with platinum and etoposide chemotherapy (localized SCLC) or with radioimmunotherapy (extensive SCLC) [Time frame: 8 months]

Secondary outcome measures (9)

• To determine the overall tolerance of the association acetazolamide and radiochemotherapy (localized SCLC) or of the association acetazolamide and radioimmunotherapy (extensive)SCLC) [Time frame: 27 months]
• To evaluate the effectiveness of the treatment [Time frame: 24 months]
• To evaluate the effectiveness of the treatment [Time frame: 24 months]
• To identify predictive factors for response to acetazolamide [Time frame: 3 months]
• To identify predictive factors for response to acetazolamide [Time frame: 30 months]
• To evaluate progression-free survival at 24 months [Time frame: 24 months]
• To evaluate overall survival at 24 months [Time frame: 24 months]
• To determine the compliance of acetazolamide [Time frame: 27 months]
• To evaluate the quality of life [Time frame: 27 months]

Eligibility criteria

Inclusion criteria

• Age > or = 18 years,
• Performance Status 0 to 2,
• Patient with an histologically non-metastatic localized (or extensive SCLC sub-group) Small cell lung cancer,
• Patient who must start radiotherapy treatment combined with chemotherapy with platinum and etoposide (localized SCLC sub-group) or Patient who received 4 cycles of chemoimmunotherapy with platinum salts, etoposide and immunotherapy (atezolizumab or durvalumab) as the first treatment (extensive SCLC sub-group) Note: The decision of the Multidisciplinary Consultation Team must be notified in the patient's medical file,
• Evaluation lesion according to the criteria RECIST 1.1 and / or according to the criteria PERCIST 1.0,
• Women of childbearing potential must have a negative serum pregnancy test within 72 hours of the first administration of the study treatment,
• If the patient is a woman of childbearing potential, she must be surgically sterile or agree to use two adequate methods of contraception throughout the duration of the study until 1 month after the last administration of the study treatment. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year, Note: Abstinence is acceptable if it is the patient's usual and preferred form of contraception,
• If the male patient has one or more female partners of childbearing age, he / she must agree to use an adequate method of contraception, starting at the first administration of the study treatment up to 1 month after the last administration of the treatment. of the study, Note: Abstinence is acceptable if it is the patient's usual and preferred form of contraception,
• Patient willing and able to provide written informed consent/assent for the trial,
• Patient affiliated with a health insurance system.

Exclusion criteria

• Patient with metastatic disease,
• History of thoracic irradiation or near / in the thoracic irradiation field,
• Patient who refuses to participate in the study or unable to agree,
• Contraindication to thoracic radiotherapy treatment: congestive heart failure unbalanced (ejection fraction <30%, clinical signs), severe respiratory failure:

• COPD grade IV according to the GOLD classification,
• Some GOLD III COPD and any patient with a respiratory defect defined as: oxygen dependence and / or FEV1 <40% normal and / or, DLCO <40% predictive value and / or vital capacity <40% predictive value,
• Contraindication to acetazolamide: hypersensitivity to acetazolamide, severe hepatic, renal or adrenal insufficiency, sulfonamide intolerance, history of renal colic, allergy to wheat other than celiac disease,
• Patient currently receiving one or more treatments described in section 6.9 of the protocol,
• History of cancer, with the exception of cancers in complete remission for more than 5 years, completely resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer,
• People particularly vulnerable as defined in Articles L.1121-5 to -8 of the French Healthcare Code, including: person deprived of freedom by an administrative or judicial decision, adult being the object of a legal protection measure or outside a state to express their consent, pregnant or breastfeeding women

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Non-randomized

Model

Parallel assignment

Masking

Open label

Primary purpose

Treatment

Study locations

France · 1 center

• Centre Antoine Lacassagne — Nice

Monaco · 1 center

• Centre Hospitalier Princesse grace — Monte Carlo

Identifiers

NCT: NCT03467360 · 2017/14 · 2022-503093-36-00 · 2017-002160-40

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗